GlassScriptPhysician profile
Jamal B Zohur
NPI 1326005430
$3,500.70
in general payments reported to CMS, 2019-2025
39 companies · $1,011 in 2025
The $1,011 reported for 2025 was more than what 85% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $204 · 2020: $206 · 2021: $137 · 2022: $124 · 2023: $931 · 2024: $887 · 2025: $1,011.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,830.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,829.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $482.86 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $392.80 | 2019-2025 | |
| Glaxosmithkline, LLC. | $339.63 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $307.79 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $164.99 | 2022-2025 | Vraylar, Linzess, Viberzi |
| E.R. Squibb & Sons, L.L.C. | $151.86 | 2020-2025 | Eliquis, Camzyos |
| Exact Sciences Corporation | $143.28 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Amgen INC. | $131.07 | 2019-2025 | Otezla, Repatha, Otezla |
| Idorsia Pharmaceuticals US INC | $125.00 | 2023 | Quviviq |
| Abbott Laboratories | $119.81 | 2019-2025 | Freestyle Libre 3 |
| Edwards Lifesciences Corporation | $92.46 | 2023-2025 | Sapien 3 Ultra Resilia |
| Harmony Biosciences LLC | $89.59 | 2021 | |
| Merck Sharp & Dohme LLC | $72.58 | 2024-2025 | Gardasil 9, Capvaxive, Gardasil |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $70.55 | 2024-2025 | Xifaxan |
| Phathom Pharmaceuticals, INC. | $68.70 | 2024 | Voquezna |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jamal Zohur listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.